October 3, 2024
Author(s): Darlene Dobkowski, MA
Fact checked by: Alex Biese
Learning more about the different symptoms and treatment goals of myeloproliferative neoplasms (MPNs) can help patients be more involved in management decisions throughout the disease trajectory, an expert said.
“It’s not just the doctor and the nurses; it’s the person who has the disease [that] is the main person, so their involvement is very important,” said Dr. Swati Goel at the recent CURE® Educated Patient® Updates in MPNs at Montefiore Medical Center in the Bronx, New York.
Goel is the Leader of the Myeloproliferative Disorder Clinic, assistant director of the hematology-oncology fellowship program and associate professor in the department of oncology and medicine at Montefiore Einstein in New York, New York.
Throughout the event, Goel discussed that there are three types of MPNs: polycythemia vera (PV), essential thrombocythemia (ET) and myelofibrosis.